1. Introduction
===============

From a public health perspective, the real-time whole-genome sequencing (WGS) of emerging viruses enables the informed development and design of molecular diagnostic assays, and tracing patterns of spread across multiple epidemiological scales (i.e. genomic epidemiology). However, WGS capacities and data sharing policies vary in different countries and jurisdictions, leading to potential sampling bias due to delayed or underrepresented sequencing data from some areas with substantial SARS-CoV-2 activity. Herein, we show that the genomic analyses of SARS-CoV-2 strains from Australian returned travellers with COVID-19 disease may provide important insights into viral diversity present in regions currently lacking genomic data.

2. SARS-CoV-2 emergence and dissemination
=========================================

In late December 2019, a cluster of cases of pneumonia of unknown aetiology in Wuhan city, Hubei province, China was reported by health authorities ([@veaa027-B22]). A novel betacoronavirus, designated SARS-CoV-2, was identified as the causative agent ([@veaa027-B21]) of the disease now known as COVID-19, with substantial human-to-human transmission ([@veaa027-B15]). To contain a growing epidemic, Chinese authorities implemented strict quarantine measures in Wuhan and surrounding areas in Hubei province. Significant delays in the global spread of the virus were achieved, but despite these measures, cases were exported to other countries. As of 9 March 2020, these numbered more than 100 countries, on all continents except Antarctica; the total number of confirmed infections exceeded 110,000 and there were nearly 4,000 deaths ([@veaa027-B2]). Although the majority of cases have occurred in China, major outbreaks have also been reported in Italy, South Korea, and Iran ([@veaa027-B19]). Importantly, there is widespread local transmission in multiple countries outside China following independent importations of infection from visitors and returned travellers.

3. WGS of SARS-CoV-2 cases in Australia and New Zealand
=======================================================

Viral extracts were prepared from respiratory tract samples where SARS-CoV-2 was detected by reverse-transcription polymerase chain reaction (RT-PCR) using [@veaa027-B20]) recommended primers and probes targeting the E and RdRp genes. In New South Wales (NSW), Australia, WGS for SARS-CoV-2 was developed based on an existing amplicon-based Illumina sequencing approach ([@veaa027-B1]). Viral extracts were reverse transcribed with SSIV VILO cDNA master mix and then used as input for multiple overlapping PCR reactions (∼2.5 kb each) spanning the viral genome using Platinum SuperFi master mix (primers provided in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Amplicons were pooled equally, purified, and quantified. Nextera XT libraries were prepared and sequencing was performed with multiplexing on an Illumina iSeq (300 cycle flow cell). In New Zealand, the ARTIC network protocol was used for WGS ([@veaa027-B17]). In short, 400-bp tiling amplicons designed with Primal Scheme ([@veaa027-B7]) were used to amplify viral cDNA prepared with SuperScript III. A sequence library was then constructed using the Oxford NanoPore ligation sequencing kit and sequenced on a R9.4.1 MinION flow cell. Near-complete viral genomes were then assembled *de novo* in Geneious Prime 2020.0.5 or through reference mapping with RAMPART V1.0.6 ([@veaa027-B11]) using the ARTIC network nCoV-2019 novel coronavirus bioinformatics protocol ([@veaa027-B14]). In total, 13 SARS-CoV-2 genomes were sequenced from cases in NSW diagnosed between 24 January and 3 March 2020, as well as a single genome from the first patient in Auckland, New Zealand sampled on 27 February 2020 ([Table 1](#veaa027-T1){ref-type="table"}). Australian and New Zealand sequences were aligned to global reference strains sourced from GISAID with MAFFT ([@veaa027-B13]) and then compared phylogenetically using a maximum-likelihood approach---PhyML v2.2.4 ([@veaa027-B10]).

###### 

SARS-CoV-2 genomes sequenced in this study

  GISAID ID        Virus name                             Location                Collection date    Travel history
  ---------------- -------------------------------------- ----------------------- ------------------ ----------------
  EPI_ISL_408976   408976/Australia/Sydney-2/2020-01-22   Sydney, Australia       22 January 2020    China
  EPI_ISL_407893   407893/Australia/NSW01/2020-01-24      Sydney, Australia       24 January 2020    China
  EPI_ISL_408977   408977/Australia/Sydney-3/2020-01-25   Sydney, Australia       25 January 2020    China
  EPI_ISL_413490   413490/New_Zealand/01/2020-02-27       Auckland, New Zealand   27 February 2020   Iran
  EPI_ISL_412975   412975/Australia/NSW05/2020-02-28      Sydney, Australia       28February 2020    Iran
  EPI_ISL_413594   413594/Australia/NSW08/2020-02-28      Sydney, Australia       28 February 2020   SE Asia
  EPI_ISL_413595   413595/Australia/NSW09/2020-02-28      Sydney, Australia       28 February 2020   SE Asia
  EPI_ISL_413213   413213/Australia/NSW06/2020-02-29      Sydney, Australia       29 February 2020   Iran
  EPI_ISL_413214   413214/Australia/NSW07/2020-02-29      Sydney, Australia       29 February 2020   None
  EPI_ISL_413596   413596/Australia/NSW10/2020-02-28      Sydney, Australia       1 March 2020       SE Asia
  EPI_ISL_413597   413597/AUS/NSW11/2020-03-02            Sydney, Australia       2 March 2020       Iran
  EPI_ISL_413600   413600/AUS/NSW14/2020-03-03            Sydney, Australia       3 March 2020       None
  EPI_ISL_413598   413598/AUS/NSW12/2020-03-04            Sydney, Australia       4 March 2020       Iran
  EPI_ISL_413599   413599/AUS/NSW13/2020-03-04            Sydney, Australia       4 March 2020       Iran

4. A distinct clade of SARS-CoV-2 identified in travellers returned from Iran
=============================================================================

The Australian strains of SARS-CoV-2 were dispersed across the global SARS-CoV-2 phylogeny ([Fig. 1A](#veaa027-F1){ref-type="fig"}). The first four cases of COVID-19 disease in NSW occurred between 24 and 26 January 2020, and these were closely related with 1--2 single nucleotide polymorphisms (SNPs) difference to the dominant variant circulating in Wuhan at the time (prototype strain MN908947/SARS-CoV-2/Wuhan-Hu-1). As the four patients identified in this period had recently returned from China, this region was the likely source of infection. From 1 February 2020, travel to Australia from mainland China was restricted to returning Australian residents and their children, who were placed in home quarantine for 14 days. Despite the intensive testing of such returning travellers, no further cases of COVID-19 were detected in NSW until 28 February 2020, when SARS-COV-2 was detected in an individual returning from Iran (NSW05). A close contact of this individual also tested positive (NSW14) providing the first evidence of local transmission within NSW. This was followed by further Iran travel-linked cases in NSW (NSW06, NSW11, NSW12, and NSW13) and New Zealand (NZ01).

![Phylogenetic analysis of SARS-CoV-2 genome sequences highlighting a clade of imported cases from Iran. (A) Global diversity of circulating SARS-CoV-2 strains including Australian sequences (blue circles, *n* = 19). The prototype strain Wuhan-Hu-1 is shown as a red circle. An emergent clade containing cases imported from Iran is highlighted with grey shading. (B) Sub-tree showing the informative branch containing imported Iranian cases (highlighted with yellow squares) and defined by substitutions at positions G1397A, T28688C, and G29742T. Node support is provided as bootstrap values of 100 replicates. For both (A) and (B), the scales are proportional to the number of substitutions per site.](veaa027f1){#veaa027-F1}

Of note, the genomes of all patients with a history of travel to Iran were part of a monophyletic group defined by three nucleotide substitutions (G1397A, T28688C, and G29742T) in the SARS-CoV-2 genome relative to the Wuhan prototype strain ([Fig. 1B](#veaa027-F1){ref-type="fig"}). G1397A and T28688C both occur in coding regions with G1397A producing a non-synonymous change (V378I) in the ORF1ab-encoded non-structural protein 2 region. G29742T occurs in the 3ʹ-UTR. In addition to the Australian and New Zealand strains, this clade also included a traveller who had returned to Canada from Iran (BC_37_0-2), providing further evidence of its likely link to the Iranian epidemic. Indeed, a search of all currently available GISAID sequences and metadata revealed no other complete genome sequences from patients with documented history of travel to or residence in Iran (as of 9 March 2020). A search of partial sequences identified two SARS-CoV-2 sequences which originated in Iran (413553/IRN/Tehran15AW/2020-02-28 and 413554/IRN/Tehran9BE/2020-02-23) spanning a 363 nt region of the viral nucleoprotein (N). Although short in length, these two sequences covered one of the informative SNPs defining this clade---T28688C, and both Iranian strains matched the sequences from patients with travel histories to Iran and grouped by phylogenetic analysis ([Supplementary Figs. S1 and S2](#sup1){ref-type="supplementary-material"}).

5. Discussion
=============

Technological advancements and the widespread adoption of WGS in pathogen genomics have transformed public health and infectious disease outbreak responses ([@veaa027-B16]). Previously, disease investigations often relied on the targeted sequencing of a small locus to identify genotypes and infer patterns of spread along with epidemiological data ([@veaa027-B3]). As seen with the recent West African Ebola ([@veaa027-B4]) and Zika virus epidemics ([@veaa027-B6]), rapid WGS significantly increases resolution of diagnosis and surveillance thereby strengthening links between genomic, clinical, and epidemiological data ([@veaa027-B5]), and potentially uncovering outbreaks in unsampled locations ([@veaa027-B8]). This advance improves our understanding of pathogen origins and spread that ultimately lead to stronger and more timely intervention and control measures ([@veaa027-B9]). Following the first release of the SARS-CoV-2 genome ([@veaa027-B21]), public health and research laboratories worldwide have rapidly shared sequences on public data repositories such as GISAID ([@veaa027-B18]) (*n* = 236 genomes as of 9 March 2020) that have been used to provide near real-time snapshots of global diversity through public analytic and visualization tools ([@veaa027-B12]).

Although all known cases linked to Iran are contained in this clade, it is important to note the presence of two Chinese strains sampled during mid-January 2020 from Hubei and Shandong provinces. It is expected that further Chinese strains will be identified that fall in this clade, and across the entire phylogenetic diversity of SARS-CoV-2 as this is where the outbreak started, including likely for the outbreak in Iran itself. However, while we cannot completely discount that the cases in Australia and New Zealand came from other sources including China, our phylogenetic analyses, as well as epidemiological (recent travel to Iran) and clinical data (date of symptom onset), provide evidence that this clade of SARS-CoV-2 is directly linked to the Iranian epidemic, from where genomic data are currently lacking. Importantly, the seemingly multiple importations of very closely related viruses from Iran into Australia suggest that this diversity reflects the early stages of SARS-CoV-2 transmission within Iran.
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